These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34196359)

  • 1. Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies.
    Chick J; Andersohn F; Guillo S; Borchert K; Toussi M; Braun S; Haas JS; Kuppan K; Lemming OM; Reines EH; Tubach F
    Alcohol Alcohol; 2021 Aug; 56(5):556-564. PubMed ID: 34196359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis.
    Aubin HJ; Dureau-Pournin C; Falissard B; Paille F; Rigaud A; Micon S; Pénichon M; Andersohn F; Truchi C; Blin P
    Alcohol Alcohol; 2021 Aug; 56(5):545-555. PubMed ID: 33969378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
    Barrio P; Ortega L; Guardia J; Roncero C; Yuguero L; Gual A
    Clin Drug Investig; 2018 Feb; 38(2):147-155. PubMed ID: 29080208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
    van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
    Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
    Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F
    PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.
    van den Brink W; Aubin HJ; Bladström A; Torup L; Gual A; Mann K
    Alcohol Alcohol; 2013; 48(5):570-8. PubMed ID: 23873853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
    van den Brink W; Sørensen P; Torup L; Mann K; Gual A;
    J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
    Higuchi S; Takahashi M; Murai Y; Tsuneyoshi K; Nakamura I; Meulien D; Miyata H
    Psychiatry Clin Neurosci; 2020 Aug; 74(8):431-438. PubMed ID: 32359104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
    Di Nicola M; De Filippis S; Martinotti G; De Risio L; Pettorruso M; De Persis S; Maremmani AGI; Maremmani I; di Giannantonio M; Janiri L
    Adv Ther; 2017 Jul; 34(7):1636-1649. PubMed ID: 28540656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
    Aubin HJ; Reimer J; Nutt DJ; Bladström A; Torup L; François C; Chick J
    Eur Addict Res; 2015; 21(3):160-168. PubMed ID: 25832297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.
    Castera P; Stewart E; Großkopf J; Brotons C; Brix Schou M; Zhang D; Steiniger Brach B; Meulien D;
    Eur Addict Res; 2018; 24(6):293-303. PubMed ID: 30485854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.
    Fitzgerald N; Angus K; Elders A; de Andrade M; Raistrick D; Heather N; McCambridge J
    Addiction; 2016 Aug; 111(8):1477-87. PubMed ID: 27262594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.